EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study

Hideo Kato iD, Takumi Umemura, Mao Hagihara, Arifumi Shiota, Nobuhiro Asai, Yukihiro Hamada, Hiroshige Mikamo, Takuya Iwamoto

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Hideo Kato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Voriconazole, Drug Monitoring, Antifungal Agents, Algorithms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although therapeutic drug monitoring (TDM) of voriconazole is performed in outpatients to prevent treatment failure and toxicity, whether TDM should be performed in all or only selected patients remains controversial. This study evaluated the association between voriconazole trough concentrations and clinical events.

Methods

We investigated the aggravation of clinical symptoms, incidence of hepatotoxicity and visual disturbances, change in co‐medications and interaction between voriconazole and co‐medications in outpatients receiving voriconazole between 2017 and 2021 in three facilities. Abnormal trough concentrations were defined as 4.0 mg/L (high group).

Results

A total of 141 outpatients (578 concentration measurements) met the inclusion criteria (treatment, 37 patients, 131 values; prophylaxis, 104 patients, 447 values). The percentages of patients with abnormal concentrations were 29.0% and 31.5% in the treatment and prophylaxis groups, respectively. Abnormal concentrations showed 50% of the concentrations at the first measurement in both therapies. Aggravation of clinical symptoms was most frequently observed in the low treatment group (18.2%). Adverse events were most common in the high group for both therapies (treatment, hepatotoxicity 6.3%, visual disturbance 18.8%; prophylaxis, hepatotoxicity 27.9%). No differences were found in changes to co‐medications and drug interactions. In the prophylaxis group, prescription duration in the presence of clinical events tended to be longer than in their absence (47.4 ± 23.4 days vs 39.7 ± 21.9 days, P = .1132).

Conclusions

We developed an algorithm based on clinical events for appropriate implementation of TDM in outpatients. However, future interventions based on this algorithm should be validated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleDrug MonitoringAntifungal AgentsAlgorithmsDrug InteractionsOutpatientsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultChemical and Drug Induced Liver InjuryYoung AdultAged, 80 and over

Stichwörter der Autor:innen

algorithmoutpatienttherapeutic drug monitoringvoriconazole

Substanzen

VoriconazoleAntifungal Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan.
  • Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan.
  • Department of Pharmacy, Tosei General Hospital, Seto, Aichi, Japan.
  • Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
  • Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.

ORCID-Profile: Hideo Kato

Förderung

  • JSPS
  • Japan Society for the Promotion of Science

Zitieren

APA

Kato, H., Umemura, T., Hagihara, M., Shiota, A., Asai, N., Hamada, Y., Mikamo, H., & Iwamoto, T. (2024). Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16004

Vancouver

Kato H, Umemura T, Hagihara M, Shiota A, Asai N, Hamada Y, et al. Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16004

BibTeX
@article{Kato2024,
  author = {Kato, Hideo and Umemura, Takumi and Hagihara, Mao and Shiota, Arifumi and Asai, Nobuhiro and Hamada, Yukihiro and Mikamo, Hiroshige and Iwamoto, Takuya},
  title = {Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16004}
}
Kostenlos starten →